Clincosm LogoSign in Get a demo

This Study in Healthy Men Tests How Different Doses of BI 1323495 Are Taken up in the Body and How Well They Are Tolerated.

Sponsor
Boehringer Ingelheim (Industry)
Overall Status
Completed
CT.gov ID
NCT03588390
Collaborator
(none)
63
Enrollment
1
Location
8
Arms
3.5
Actual Duration (Months)
18.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective of this trial is to investigate the safety and tolerability of BI 1323495 in healthy male subjects following oral administration of single rising doses.

Secondary objectives are the exploration of the pharmacokinetics (PK) including dose proportionality and pharmacodynamics (PD) of BI 1323495 after single dosing and the assessment of the PK/PD relationship.

Condition or Disease Intervention/Treatment Phase
  • Drug: BI 1323495
  • Drug: BI 1323495
  • Drug: BI 1323495
  • Drug: Placebo
  • Drug: Placebo
  • Drug: Placebo
 Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
63 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BI 1323495 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)
Actual Study Start Date :
Jul 31, 2018
Actual Primary Completion Date :
Nov 14, 2018
Actual Study Completion Date :
Nov 14, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Dose Group 1

Drug: BI 1323495
Low strength tablet

Drug: Placebo
Placebo to low strength tablet
Experimental: Dose Group 2

Drug: BI 1323495
Low strength tablet

Drug: Placebo
Placebo to low strength tablet
Experimental: Dose Group 3

Drug: BI 1323495
Low strength tablet

Drug: Placebo
Placebo to low strength tablet
Experimental: Dose Group 4

Drug: BI 1323495
Middle strength tablet

Drug: Placebo
Placebo to middle strength tablet
Experimental: Dose Group 5

Drug: BI 1323495
Middle strength tablet

Drug: Placebo
Placebo to middle strength tablet
Experimental: Dose Group 6

Drug: BI 1323495
Middle strength tablet

Drug: Placebo
Placebo to middle strength tablet
Experimental: Dose Group 7

Drug: BI 1323495
High strength tablet

Drug: Placebo
Placebo to high strength tablet
Experimental: Dose Group 8

Drug: BI 1323495
High strength tablet

Drug: Placebo
Placebo to high strength tablet

Outcome Measures

Primary Outcome Measures

  1. Number [N (%)] of subjects with drug-related adverse events [Up to day 15]

Secondary Outcome Measures

  1. AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) [Up to day 15]

  2. Cmax (maximum measured concentration of the analyte in plasma) [Up to day 15]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Healthy male subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs (Blood Pressure [BP], Pulse Rate [PR]), 12-lead Electrocardiogram [ECG], and clinical laboratory tests

  • Age of 18 to 45 years (incl.)

  • Body Mass Index [BMI] of 18.5 to 29.9 kg/m2 (incl.)

  • Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice[ GCP] and local legislation

Exclusion Criteria:

  • Any finding in the medical examination (including Blood Pressure [BP], Pulse Rate [PR] or Electrocardiogram [ECG]) is deviating from normal and judged as clinically relevant by the investigator

  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm

  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance

  • Any evidence of a concomitant disease judged as clinically relevant by the investigator

  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders

  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)

  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders

  • History of relevant orthostatic hypotension, fainting spells, or blackouts

  • Chronic or relevant acute infections

  • History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)

  • Use of drugs within 30 days prior to administration of trial medication if that might reasonably influence the results of the trial (incl. QT/QTc interval prolongation)

  • Participation in another trial where an investigational drug has been administered within 60 days prior to planned administration of trial medication, or current participation in another trial involving administration of investigational drug

  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)

  • Inability to refrain from smoking on specified trial days

  • Alcohol abuse (consumption of more than 30 g per day)

  • Drug abuse or positive drug screening

  • Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial

  • Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial

  • Inability to comply with dietary regimen of trial site

  • A marked baseline prolongation of QT/QTc interval such as QTc intervals that are repeatedly greater than 450 ms or any other relevant ECG finding at screening

  • A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)

  • Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study

In addition, the following trial-specific exclusion criteria apply:

  • Male subjects with female partner of childbearing potential who are unwilling to use male contraception (condom or sexual abstinence) from the first administration of trial medication until 30 days after last administration of trial medication

  • Current or history of relevant kidney, urinary tract diseases or abnormalities (e.g. nephrolithiasis, hydronephrosis, acute or chronic nephritis, renal injury, renal failure)

  • Estimated glomerular filtration rate according to CKD-EPI formula < 90 mL/min at screening

  • Within 10 days prior to administration of trial medication, use of any drug that could reasonably inhibit platelet aggregation or coagulation (e.g., acetylsalicylic acid)

  • Further exclusion criteria apply

Contacts and Locations

Locations

Site City State Country Postal Code
1 Humanpharmakologisches Zentrum Biberach Biberach Germany 88397

Sponsors and Collaborators

  • Boehringer Ingelheim

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT03588390
Other Study ID Numbers:
  • 1405-0001
  • 2017-004899-62
First Posted:
Jul 17, 2018
Last Update Posted:
Jan 17, 2019
Last Verified:
Nov 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jan 17, 2019